Sep 2, 2026 | Legal Compliance, News, Risk Management
The U.S. Food and Drug Administration (FDA) has issued a detailed Warning Letter (CBER 26-726330) to Scottsdale, Arizona-based R3 Medical Companies, its affiliated entities Bello Bio, LLC and Regen Suppliers, LLC, and CEO David L. Greene, M.D. Following joint facility...
Sep 1, 2026 | Legal Compliance, News, State-Specific Regulations
Mississippi’s three healthcare licensing boards have put the state’s providers on notice: there is no safe harbor for offering “research-grade” peptides to patients. In a joint statement issued by the Mississippi State Board of Medical...
Aug 13, 2026 | Legal Compliance
In 2025, the Fifth Circuit’s Zyla Life Sciences, LLC v. Wells Pharma of Houston, LLC included a passing, non-binding comment suggesting that brand-name manufacturers might sue compounders under state unfair-competition laws for selling unapproved “new...
Aug 13, 2026 | Legal Compliance, News
Eli Lilly & Co. has significantly escalated its legal campaign against the illicit trade of its investigational weight-loss drug, retatrutide. The pharmaceutical giant filed lawsuits in federal court against six U.S.-based businesses—including medical spas,...
Aug 7, 2026 | Legal Compliance, News
Driven by booming consumer demand for anti-aging, weight-loss, and performance-enhancing therapies, integrative clinics, medical spas, and online vendors have rushed to offer popular compounds like BPC-157 and TB-500. Two recent developments expose a dangerous gap...
Aug 3, 2026 | Legal Compliance, News
If your medical spa or aesthetic practice relies on major dermal filler brands, a major legal filing in federal court deserves your attention. On July 21, 2026, Allergan, Inc. and its parent company, AbbVie, filed a patent-infringement lawsuit against Galderma Group...
